ANI Pharmaceuticals, Inc. EPS (Earnings per Share) 2009–2025
ANI Pharmaceuticals, Inc. reported $3.32 of earnings per share for fiscal 2025. That was 419.2% higher than fiscal 2024. Compared with fiscal 2020, the change was +276.6%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $3.32 | +419.2% |
| FY 2024 | $-1.04 | -222.4% |
| FY 2023 | $0.85 | +127.9% |
| FY 2022 | $-3.05 | +10.3% |
| FY 2021 | $-3.40 | -80.9% |
| FY 2020 | $-1.88 | -476.0% |
| FY 2019 | $0.50 | -61.5% |
| FY 2018 | $1.30 | +1544.4% |
| FY 2017 | $-0.09 | -126.5% |
| FY 2016 | $0.34 | -74.2% |
| FY 2015 | $1.32 | -49.0% |
| FY 2014 | $2.59 | +381.5% |
| FY 2013 | $-0.92 | +27.6% |
| FY 2012 | $-1.27 | +59.7% |
| FY 2011 | $-3.15 | +25.2% |
| FY 2010 | $-4.21 | +49.9% |
| FY 2009 | $-8.40 | — |
Source: ANI Pharmaceuticals, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ANIP 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ANI Pharmaceuticals, Inc. reported $3.32 of earnings per share for fiscal 2025. That was 419.2% higher than fiscal 2024. Compared with fiscal 2020, the change was +276.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ANI Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s earnings per share?
ANI Pharmaceuticals, Inc. (ANIP) reported earnings per share of $3.32 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.